For example, in glioblastoma, the combination of ETO and temozolomide (a standard chemotherapeutic) inhibits tumor invasion [136], while in TNBC, ETO synergizes with EZH2 inhibitors to significantly enhance therapeutic efficacy [137]. Here, RUNX1T1 is linked to neoplasm.